Super Session 7 - Early Stage Financing
Thursday, September 10, 2015
•
S17
•
10:00 AM
>
11:00 AM
•
Super Session 7 - Early Stage Financing
•
Plenary Room A2
Session hosted by Vinnova
Early stage financing for commercial biotechnology continues to challenge SMEs and funders, both private and public, across Europe. The combined pressure of reduced spending power (especially public) but increased demands, funders and policy makers are refining finance for maximum impact on the early stage technologies that strive for maturity. The pressure on pharma to provide new products, on governments to make public health care more efficient and on all parties to align development for reduced fragmentation helps to focus topics and maturation priorities for early stage funding.
This session looks at how current funding mechanisms are evolving and new funding programmes emerging at national, European and global level to support the next generation of SMEs. Bringing the expertise of VINNOVA to the fore, the panel will give a snapshot of funding programmes and discuss with the audience, how the future of funding needs to look.
Moderator: Dr Claire Skentelbery, Secretary General, European Biotechnology Network asbl
Speakers:
Dr. Jenni Nordborg, Head of Department Health Division, Vinnova
Mr. Reidar Gårdebäck, Director, Medtech4Health
Mr. Peter Nordström, Programme Director, SweLife, Sweden
Dr. Anna Kristine Larsen, Scientific Office, Innovationsfonden
Dr. Gunnar Sandberg, Programme Director EUREKA, Vinnova
Dr. Max Felhmann, President & CEO, Neomed Institute
|